DOI:
10.1055/s-00000069
Seminars in Liver Disease
LinksClose Window
References
Bi F, Qin S, Gu S. et al.
Donafenib versus sorafenib as first-line therapy in advanced hepatocellular carcinoma: an open-label, randomized, multicenter phase ii/iii trial.
J Clin Oncol 2020;
38 (suppl): Abstract 4506
Search in:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.